Document is current

Article History

Received: 15 January 2025

Accepted: 24 March 2025

First Online: 5 April 2025

Declarations

:

: The protocol was centrally reviewed and approved by the Certified Review Board of the Nagoya University Graduate School of Medicine (2020 − 0303), and was registered with the Japan Registry of Clinical Trials (jRCTs041200048). The present study was conducted in accordance with the Clinical Trials Act, and complied with the Declaration of Helsinki. Written informed consent was obtained from all patients.

: Not applicable.

: SA has received grant/research support, consulting fees, and/or speakers’ fees from AbbVie, Asahi Kasei, Astellas, Ayumi, Chugai, Eisai, Eli Lilly, Taisho, and UCB Japan. TK has received grant/research support and/or speakers’ fees from AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, and Pfizer. HH has received grant/research support and/or speakers’ fees from Japan Research Foundation Clinical Pharmacology, AbbVie, Asahi Kasei, Astellas, AstraZeneca, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Nihon Pharmaceutical, Ono, and Taisho. YK has received speakers’ fees from Asahi Kasei, Astellas, Eisai, and Eli Lilly. YH has received speakers’ fees from Astellas and UCB Japan. TH has received speakers’ fees from AbbVie, Asahi Kasei, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, and Pfizer. HY has received grant/research support and/or speakers’ fees from AbbVie, Asahi Kasei, Astellas, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Kissei, Janssen, Nippon Shinyaku, Mitsubishi Tanabe, Novartis, Pfizer, Sanofi, Taisho, Takeda, Teijin, and Viatris. YK has received speakers’ fees from Astellas. KM has received speakers’ fees from Mitsubishi Tanabe and Pfizer, and is affiliated with an endowed department sponsored by Ayumi, Mitsubishi Tanabe, and UCB Japan. KM has received speakers’ fees from AbbVie, Asahi Kasei, Astellas, Boehringer Ingelheim, Chugai, Eisai, Eli Lilly, Gilead, Mitsubishi Tanabe, Mochida, Novartis, Ono, Pfizer, Taisho, Takeda, UCB Japan, and Viatris. MS has received speakers’ fees from AbbVie, Asahi Kasei, Astellas, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Mitsubishi Tanabe, Novartis, Pfizer, Sanofi, Taisho, Takeda, and UCB Japan. KT has received grant/research support and/or speakers’ fees from AbbVie, Asahi Kasei, Astellas, Chugai, Eisai, Gilead, Japan Rheumatism Foundation, Mitsubishi Tanabe, Novo Nordisk, Pfizer, Sanofi, and UCB Japan. All other authors declare no conflicts of interest.